optic neuritis glp 1 Do GLP-1 Medications Cause Eye Problems? Understanding the NAION Risk – Revolution Health & Wellness Small NAION Risk from GLP-1

Quick Stats for Obesity GLP-1 Market Obesity GLP-1 Market Value (2025): USD 8,169 million Obesity GLP-1 Market Forecast Value (2035): USD 65,364 million Obesity GLP-1 Market Forecast CAGR: 23.1% Leading Molecule Class in Obesity GLP-1 Market: Semaglutide (58.0%) Key Growth Regions in Obesity GLP-1 Market: North America, Europe, and East Asia Top Key Players in Obesity GLP-1 Market: Novo Nordisk, Eli Lilly, and emerging manufacturers Between 2025 and 2030, the obesity GLP-1 market is projected to expand from USD 8169.0 million to USD 39,528 million, resulting in a value increase of USD 31359.0 million, which represents 54.8% of the total forecast growth for the decade

doi: 10.1210/endo.142.5.8128 50 BnemannMGerhardsteinBLGaoTHoseyMM

The medication is HSA/FSA eligible, making it accessible to more patients pursuing weight loss without insurance barriers

Proc Natl Acad Sci USA 2010

Which region is expected to witness the highest growth rate in the next 5 years